Transcenta Holding Limited (HKG:6628)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.520
+0.110 (7.80%)
May 29, 2025, 1:42 PM HKT

Transcenta Holding Company Description

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States.

It develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST808, a humanized antibody regulating B/plasma cell; TST005, a PD-L1/TGF-β bi-functional protein candidate for solid tumors; TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases.

It also develops TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing; TST003, a regulatory protein expressed by stromal cells and tumor cells, including colon, prostate, gastric, lung, esophageal, pancreatic, and breast cancers; TST006, a bi-specific claudin 18.2/PD-L1 antibody for solid tumors; TST008, a bi-functional antibody for MASP-2 and BAFF for autoimmune diseases; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors; TST012 and TST013, an ADC candidate targeting biomarker expressing gastric cancer and other solid tumors; TST801, a bifunctional fusion protein for autoimmune diseases; and TST105, a bispecific ADC candidate targeting FGFR2b and an undisclosed tumor.

The company has a partnership and collaboration agreements with Bristol Myers Squibb and Eli Lilly & Company; research collaboration with Alebund Pharmaceuticals, Dana Farber Cancer Institute, and John Hopkins University.

The company was formerly known as MabSpace International Limited and changed its name to Transcenta Holding Limited in June 2019.

Transcenta Holding Limited was incorporated in 2010 and is headquartered in Suzhou, the People’s Republic of China.

Transcenta Holding Limited
Country Cayman Islands
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 184
CEO Xueming Qian

Contact Details

Address:
B6-501, 218 Xinghu Street
Suzhou, 215123
China
Phone 86 12 6707 9200
Website transcenta.com

Stock Details

Ticker Symbol 6628
Exchange Hong Kong Stock Exchange
Fiscal Year January - December
Reporting Currency CNY
ISIN Number KYG9005B1041
SIC Code 2836

Key Executives

Name Position
Dr. Li Xu M.D. Head of CDx, Member of Scientific Advisory Board, Strategic Advisor to Chief Executive Officer and Non-Executive Director
Dr. Xueming Qian Ph.D. Executive Chairman and Chief Executive Officer
Weiwei Liang M.B.A. Acting Chief Financial Officer, Senior Vice President of Business Development Transaction and Corporate Strategy
Dr. Christopher Hwang Ph.D. Executive Vice President of Process Development and Chief Technology Officer
Wei Wang Vice President of Investor Relations and Capital Markets Department and Secretary to the Board
Dr. Yi Gu Ph.D. Senior Vice President and Head of Research
Dr. Charlie Qi M.D. Senior Vice President of Global Clinical Development
Dr. Wen-I Chang Ph.D. Senior Vice President of Oncology Franchise Strategy
Dr. Caroline Germa M.D., Ph.D. Executive Vice President of Global Medicine Development and Chief Medical Officer
Fan Zhang SVice President of Process Development